
Signatera™ Proves Powerful Post-Surgery Predictor in PALLAS Phase III Study
Natera Unveils First Translational Insights From Phase III PALLAS Trial, Demonstrating Strong Prognostic Power of Signatera MRD Testing in HR+/HER2- Breast Cancer A global leader in cell-free DNA–based testing and precision oncology, has released the first translational research findings from…












